VT-111 is being developed as a therapeutic to prevent damage due to inflammation, in particular cardiovascular inflammation and inflammation caused by solid organ transplantation.  As Viron's lead candidate, it is the first example from its pipeline of a viral anti-inflammatory protein being successfully adapted into a therapeutic for the treatment of human disease.

VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition ^(1,2).  VT-111 is an extremely potent inhibitor of monocyte migration during vascular inflammation at doses much lower (in µg/kg doses) than most biologics on the market today. VT-111 dramatically reduces leukocyte recruitment to sites of inflammation at low doses in vivo and has demonstrated efficacy in more than 40 animal models of disease including those for angioplasty, stent placement, cardiovascular bypass surgery and solid organ (heart and kidney) transplantation.

VT-111 has demonstrated a favorable safety profile in two clinical trials. The drug is currently undergoing manufacturing sacle-up for late stage clinical trials and market launch, and preparations to file an IND in solid organ transplant, its second indication.